Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCDIN3D | Q7Z5W3 | 15/20 | 0.52 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23579680 | 0.95 | HTR2C (0.55) | BCDIN3DPDE2AHTR2CSHMT2 | |
| SCHEMBL23579931 | 0.87 | CA1 (0.60) | BCDIN3DPDE2AHTR2CKDM4ENPC1 | |
| SCHEMBL30033469 | 0.87 | CA1 (0.60) | BCDIN3DPDE2AHTR2CKDM4ENPC1 | |
| SCHEMBL23580247 | 0.86 | BCDIN3D (0.65) | BCDIN3DPDE2AHTR2CKDM4ENPC1 | |
| SCHEMBL23579807 | 0.86 | CA1 (0.62) | BCDIN3DPDE2AHTR2CKDM4ENPC1 | |
| SCHEMBL23580265 | 0.84 | BCDIN3D (0.56) | BCDIN3DPDE2AKDM4ENPC1MAPT | |
| SCHEMBL23579838 | 0.82 | PDE5A (0.62) | BCDIN3DHTR2CMAPT | |
| SCHEMBL30034185 | 0.82 | PDE5A (0.62) | BCDIN3DHTR2CMAPT | |
| SCHEMBL23579698 | 0.82 | PDE2A (0.55) | BCDIN3DPDE2AHTR2C | |
| SCHEMBL23579797 | 0.82 | PDE2A (0.55) | BCDIN3DPDE2AKDM4ENPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151550-B | External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof | 桑福德·伯纳姆·普雷比医学发现研究所 | 2024-11-22 | — | — | CN | disclosed |
| US-20230121698-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-20 | — | — | US | disclosed |
| EP-4081528-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115151550-A | Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof | 桑福德·伯纳姆·普雷比医学发现研究所 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021133915-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133915-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121698-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | ENPP1, ENPP3, PPA1 | BCDIN3D 582/4885PDE2A 37/4885HTR2C 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.